TICKERNERD
Menu
QTTBQTTBHealthcare · Biotechnology

QTTB Stock Forecast: Q32 Bio, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$11
+3.54% on the day

The 6 Wall Street analysts covering Q32 Bio, Inc. hold a median 12-month price target of $36 — +224.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 85 of 100 as at 12 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$330.4M
Ticker Nerd rank
85 / 100
Median analyst target
$36
Analysts covering
6
Revenue$0.0
Operating income−$9.1M
Net income−$8.9M
Free cash flow−$3.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−13.3%
1M
−28.0%
YTD
+234.3%
1Y
+490.4%
From 52W high
−48.1%
From 52W low
+537.9%
$2
$21
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

QTTB stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Q32 Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
85 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
94
Quality
89
Value
79
Revisions
66
Growth
64
Volatility
60
Size
60
Issuance
57
Accruals
17

Momentum (94): The shares have been drifting up relative to others.

Accruals (17): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

QTTB stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on QTTB, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50$60Oct 25Jan 26Apr 26Jul 26QTTBHigh $59Median $36Low $34

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
6 Buy0 Hold0 Sell
Low $34Median $36High $59

The green dot is the last close — the median target sits +224.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
24 Aug 2026Morgan StanleyInitiatesOverweight$34
28 July 2026HC Wainwright & Co.MaintainsBuy—
28 July 2026HC Wainwright & Co.MaintainsBuy$13 → $36
13 July 2026OppenheimerMaintainsOutperform—
13 July 2026OppenheimerMaintainsOutperform$20 → $40
13 July 2026Wells FargoUpgradeOverweight$66
13 July 2026Wells FargoUpgradeOverweight—
22 May 2026MizuhoInitiatesOutperform$14
22 May 2026MizuhoInitiatesOutperform—
18 May 2026Cantor FitzgeraldInitiatesOverweight—
5 May 2026HC Wainwright & Co.ReiteratesBuy—
25 Feb 2026HC Wainwright & Co.InitiatesBuy—
12 Mar 2025Wells FargoMaintainsEqual-Weight—
11 Feb 2025BMO CapitalDowngradeMarket Perform—
11 Feb 2025Piper SandlerDowngradeNeutral—
12 Dec 2024BMO CapitalMaintainsOutperform—
12 Dec 2024GuggenheimDowngradeNeutral—
11 Dec 2024Leerink PartnersDowngradeMarket Perform—
11 Dec 2024OppenheimerMaintainsOutperform—
11 Dec 2024Piper SandlerMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. QTTB appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

QTTB vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Q32 Bio, Inc. returned +490.4% against +17.5% for the S&P 500, dividends included.

QTTB vs S&P 500, last 12 monthsTotal return, rebased to 100
02004006008001,000Oct 25Jan 26Apr 26Jul 26QTTBS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

QTTB analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Q32 Bio, Inc. (QTTB) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
3.5×

Cheaper than 67% of US stocks

Price / sales
6.1×

Cheaper than 21% of US stocks

Price / book
2.5×

Cheaper than 38% of US stocks

EV / EBITDA
10.5×

Cheaper than 36% of US stocks

Growth & margins
Revenue growth (YoY)
−100.0%

Higher than 1% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
39.9%

Higher than 92% of US stocks

Net margin
62.9%

Higher than 97% of US stocks

Returns & dividend
Return on equity
72.1%

Higher than 95% of US stocks

Return on assets
14.7%

Higher than 97% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Q32 Bio, Inc. (QTTB) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Q32 Bio, Inc. has a market value of $330.4M and an enterprise value of $229.5M.

  • Revenue in the twelve months to 30 June 2026: $53.7M. The latest quarter shrank 100.0% year on year.

  • Net income over the same four quarters: $33.8M, a 62.9% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$19.8M.

  • Shares outstanding: 29.8M.

  • Trailing P/E: 3.5×; forward P/E: −10.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Q32 Bio, Inc. employs 22 people — $2.4M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Sept 2026

Data provided by Twelve Data

Peers

QTTB vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
QTTBQ32 Bio, Inc.$330.4M
85
ZNTLZentalis Pharmaceuticals, Inc.$332.3M
62
LXEOLexeo Therapeutics, Inc.$333.7M
29
IKTInhibikase Therapeutics, Inc.$326.5M
33
OCGNOcugen, Inc.$345.3M
22
XFORX4 Pharmaceuticals, Inc.$347.0M
62
UPBUpstream Bio, Inc.$313.8M
27

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Q32 Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest QTTB news & analysis

Down 23.1% in 4 Weeks, Here's Why Q32 Bio (QTTB) Looks Ripe for a Turnaround

Zacks Investment Research · 7 Sept 2026positive

Q32 Bio (QTTB) has declined 23.1% over the past four weeks and is now considered technically oversold. Zacks reports that strong agreement among Wall Street analysts in revising earnings estimates higher suggests the stock may be positioned for a trend reversal.

Why it matters — QTTB watchers would care because the oversold condition combined with upward earnings estimate revisions points to a possible turnaround for the stock.

Q32 Bio to Participate in Upcoming September Investor Conferences

PRNewsWire · 1 Sept 2026neutral

Q32 Bio announced that its management will participate in three investor conferences in September, beginning with a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on September 8, 2026. Q32 Bio is a clinical-stage biotechnology company developing therapies for alopecia areata and other autoimmune and inflammatory diseases.

Why it matters — The conference appearances give investors and QTTB watchers an opportunity to hear directly from company management about its clinical-stage programs.

Wall Street Analysts See an 182.18% Upside in Q32 Bio (QTTB): Can the Stock Really Move This High?

Zacks Investment Research · 17 Aug 2026positive

Wall Street analysts' average price target for Q32 Bio (QTTB) implies a potential upside of roughly 182.2%. According to Zacks, a positive trend in earnings estimate revisions may support further upside in the stock, though the reliability of consensus price targets is questioned.

Why it matters — A QTTB watcher would care because analyst price targets and earnings estimate revisions are signals that bear on market expectations for the company's outlook.

Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

PRNewsWire · 5 Aug 2026positive

Q32 Bio reported second quarter 2026 financial results and corporate updates on August 5, 2026. The company announced positive bempikibart 36-week topline results from Part B of the SIGNAL-AA trial, continued enrollment in the open-label extension, plans for a registration-directed program in severe/very severe alopecia areata in the first half of 2027, and completed a $200 million public offering in July 2026. It reported cash and cash equivalents of $106.3 million as of June 30, 2026, which combined with offering proceeds is expected to fund operations through Phase 3 topline results.

Why it matters — The positive trial data, planned registration-directed program, and strengthened cash position give QTTB watchers a clearer picture of the company's financial runway and development path for bempikibart.

Wall Street Analysts Think Q32 Bio (QTTB) Could Surge 185.99%: Read This Before Placing a Bet

Zacks Investment Research · 31 July 2026positive

Zacks Investment Research reported that the consensus price target for Q32 Bio (QTTB) suggests a potential 186% upside, while noting that such price targets are often not reliable indicators. The article points to an upward trend in earnings estimate revisions as a more meaningful signal of possible near-term gains.

Why it matters — QTTB watchers would care because the article highlights shifting analyst earnings expectations, which can influence investor sentiment and stock movement regardless of whether the price target is achieved.

FAQ

Frequently asked questions about QTTB stock

What is the QTTB stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Q32 Bio, Inc. have a median 12-month price target of $36, with estimates ranging from $34 to $59. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is QTTB stock a buy right now?

Of the 6 analysts covering Q32 Bio, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Q32 Bio, Inc. 85 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank QTTB?

As at 12 Sept 2026, Q32 Bio, Inc. ranks 85 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (94 of 100).

Will QTTB stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +224.3% from the last close, and Ticker Nerd's factor model ranks Q32 Bio, Inc. 85 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the QTTB stock forecast for 2030?

No analyst covering Q32 Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for QTTB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $34 to $59 over the next 12 months.

How has QTTB stock performed over the past year?

Q32 Bio, Inc. returned +490.4% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Q32 Bio, Inc. do?

Q32 Bio Inc. is a clinical-stage biotechnology company focused on developing biologic therapies for autoimmune and inflammatory diseases driven by immune system dysfunction.

What is the latest news on QTTB?

The most recent item we track (Zacks Investment Research, 7 Sept 2026): "Down 23.1% in 4 Weeks, Here's Why Q32 Bio (QTTB) Looks Ripe for a Turnaround". Q32 Bio (QTTB) has declined 23.1% over the past four weeks and is now considered technically oversold. Zacks reports that strong agreement among Wall Street analysts in revising earnings estimates higher suggests the stock may be positioned for a trend reversal.

Company

About Q32 Bio, Inc.

Q32 Bio Inc. is a clinical-stage biotechnology company focused on developing biologic therapies for autoimmune and inflammatory diseases driven by immune system dysfunction. The company’s current programs center on restoring healthy immune balance through targeted modulation of the adaptive and innate immune systems, with a lead emphasis on treatments for alopecia areata and other immune-mediated conditions. Q32 Bio’s pipeline includes bempikibart, an antibody-based candidate designed to regulate immune signaling in dermatology and related autoimmune settings, as well as research efforts in complement-pathway biology for tissue-targeted immune control. The company’s work is positioned within the broader biopharmaceutical sector, where precision immunology and biologics play an important role in addressing chronic diseases with limited treatment options. Based in Waltham, Massachusetts, Q32 Bio continues to operate as a research-focused company advancing specialized therapies from clinical development programs.

CEO Ms. Jodie Pope Morrison · 22 employees · United States · https://www.q32bio.com